The first 60 days: Mesothelioma
An asbestos-caused cancer of the lung lining. Immunotherapy doublets replaced chemotherapy in 2020, and mesothelin CAR-T is under study. Below, week by week, is what OnCo's record of Mesothelioma says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
- Diagnosis and stagingNCCN category MPM guideline, NCCN Mesothelioma: Pleural v1.2026
CT and PET/CT; thoracoscopic biopsy with IHC panel (calretinin, WT1, D2-40; BAP1 and MTAP loss support malignancy); histology and BAP1/MTAP status recorded for treatment planning.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- PathologistNamed in the standard of care for: Diagnosis and staging.
- RadiologistNamed in the standard of care for: Diagnosis and staging.
- SurgeonNamed in the standard of care for: Surgery, Radiotherapy, Peritoneal mesothelioma.
- Medical oncologistNamed in the standard of care for: Unresectable, First line, non-epithelioid, First line, epithelioid, Maintenance and 2 more.
- Clinical oncologist (radiotherapy)Named in the standard of care for: Radiotherapy.
- Palliative and supportive care teamNamed in the standard of care for: Radiotherapy.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Not recommended for cure outside trials after MARS 2; VATS pleurodesis or indwelling pleural catheter for effusion; extended pleurectomy/decortication (P/D) only in clinical trials.
Nivolumab-ipilimumab or chemo-IO; TTFields.
Nivolumab + ipilimumab (CheckMate 743) preferred; pembrolizumab + platinum-pemetrexed alternative.
Pembrolizumab + platinum-pemetrexed, nivolumab + ipilimumab, or platinum-pemetrexed ± bevacizumab, chosen by fitness and preference.
Palliative for chest wall pain; prophylactic tract irradiation not beneficial (SMART/PIT trials); hemithoracic IMRT after surgery only in trials.
Cytoreductive surgery with HIPEC in selected patients; systemic therapy extrapolated from pleural disease.
Nivolumab (CONFIRM: OS benefit vs placebo) or nivolumab-ipilimumab if not given first line; platinum-pemetrexed rechallenge or gemcitabine/vinorelbine if IO given first; trials.
Continue immunotherapy per regimen; TTFields (Optune Lua) with pemetrexed-platinum under HDE approval; no maintenance chemotherapy standard.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example Histology, BAP1, CDKN2A/MTAP deletion, Mesothelin, Histologydrives first-line choice), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Epithelioid, Biphasic, Sarcomatoid.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Unresectable
- For my situation (unresectable), which of the standard options do you recommend and why?Guideline options include: Nivolumab-ipilimumab or chemo-IO; TTFields.
- Am I a candidate for Nivolumab, Ipilimumab, Pembrolizumab or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Diagnosis and staging
- For my situation (diagnosis and staging), which of the standard options do you recommend and why?Guideline options include: CT and PET/CT; thoracoscopic biopsy with IHC panel (calretinin, WT1, D2-40; BAP1 and MTAP loss support malignancy); histology and BAP1/MTAP status recorded for treatment planning.
First line, non-epithelioid
- For my situation (first line, non-epithelioid), which of the standard options do you recommend and why?Guideline options include: Nivolumab + ipilimumab (CheckMate 743) preferred; pembrolizumab + platinum-pemetrexed alternative.
- Am I a candidate for Nivolumab, Ipilimumab, Pembrolizumab, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of CheckMate 743 and IND.227 / KEYNOTE-483 apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
First line, epithelioid
- For my situation (first line, epithelioid), which of the standard options do you recommend and why?Guideline options include: Pembrolizumab + platinum-pemetrexed, nivolumab + ipilimumab, or platinum-pemetrexed ± bevacizumab, chosen by fitness and preference.
- Am I a candidate for Pembrolizumab, Nivolumab, Ipilimumab or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of IND.227 / KEYNOTE-483 and MAPS apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Maintenance
- For my situation (maintenance), which of the standard options do you recommend and why?Guideline options include: Continue immunotherapy per regimen; TTFields (Optune Lua) with pemetrexed-platinum under HDE approval; no maintenance chemotherapy standard.
- Am I a candidate for Optune / Optune Pax (TTFields), and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of STELLAR apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Second line
- For my situation (second line), which of the standard options do you recommend and why?Guideline options include: Nivolumab (CONFIRM: OS benefit vs placebo) or nivolumab-ipilimumab if not given first line; platinum-pemetrexed rechallenge or gemcitabine/vinorelbine if IO given first; trials.
- Am I a candidate for Nivolumab, Pemetrexed, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Surgery
- For my situation (surgery), which of the standard options do you recommend and why?Guideline options include: Not recommended for cure outside trials after MARS 2; VATS pleurodesis or indwelling pleural catheter for effusion; extended pleurectomy/decortication (P/D) only in clinical trials.
- How do the results of MARS 2 apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Radiotherapy
- For my situation (radiotherapy), which of the standard options do you recommend and why?Guideline options include: Palliative for chest wall pain; prophylactic tract irradiation not beneficial (SMART/PIT trials); hemithoracic IMRT after surgery only in trials.
Peritoneal mesothelioma
- For my situation (peritoneal mesothelioma), which of the standard options do you recommend and why?Guideline options include: Cytoreductive surgery with HIPEC in selected patients; systemic therapy extrapolated from pleural disease.
Any stage
- Are there clinical trials I could join, for example of Synthetic lethality approaches, EB-MF-CAR-NK-01, Anetumab ravtansine, Antibody-drug conjugates for mesothelioma: why they have failed so far and how they could work?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “Sarcomatoid subtype”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “No early detection despite known exposure”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Trials open now for this cancer in OnCo, largest phase first. Joining a trial is a decision like any other: ask what the comparison arm is, whether a placebo is used, and what happens if you leave. The cancer page searches ClinicalTrials.gov live for more.
- MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural MesotheliomaPhase 3 · active · NCT06097728A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (eVOLVE-Meso)
- Hemithoracic irradiation with proton therapy in malignant pleural mesothelioma (UCL)Phase 2 · recruiting · NCT05655078Malignant pleural mesothelioma; hemithoracic proton beam therapy to the whole pleural surface, a technique that protects the heart, opposite lung and liver better than photon radiotherapy; started March 2024, 148 planned
- Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant MesotheliomaPhase 2 · active · NCT01843374A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma
- Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid TumorsPhase 2 · recruiting · NCT06535607A Phase II, Multi-Center Study to Evaluate the Efficacy and Safety of Volrustomig as Monotherapy or in Combination With Anti-cancer Agents in Participants With Advanced/Metastatic Solid Tumors
- A 2-part Phase 1/2 Open-label Trial on ODM-212Phase 1/2 · recruiting · NCT07563738A 2-part Phase 1/2 Open-label Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ODM-212 in Combination With Anti-cancer Therapy in Participants With Advanced Solid Tumours
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Mesothelioma: the full pageAn asbestos-caused cancer of the lung lining. Immunotherapy doublets replaced chemotherapy in 2020, and mesothelin CAR-T is under study.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- Epithelioid vs sarcomatoid (biphasic) mesothelioma: Mesothelioma comes in a slower 'epithelioid' form and an aggressive 'sarcomatoid' form.
- Synthetic lethality: Two genes where losing either alone is fine but losing both kills the cell.
- Pleura: The two-layered lining around each lung.
- Pneumonectomy: Removing an entire lung.
- Pleurodesis and indwelling pleural catheter: Ways to stop fluid repeatedly collecting around the lung: either glue the two pleural layers together with talc, or leave a small tunnelled drain the patient empties at home.
- Malignant pleural effusion and ascites: Fluid that builds up around the lung (pleural effusion) or in the abdomen (ascites) because cancer cells irritate the lining and block lymph drainage; it causes breathlessness or a swollen, tight belly.
- Peritoneum and peritoneal metastases: The thin membrane lining the abdominal cavity and covering the bowel.
- Immune-related adverse events (irAEs): Immune-related adverse events (irAEs) are the autoimmune side effects of checkpoint inhibitors: colitis, thyroid problems, rash, hepatitis, pneumonitis.
Every term links to the glossary.